- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears AI-Powered Muscle Health Analysis Derived from Rapid MRI Scans
Based off rapid magnetic resonance imaging (MRI), the AI-enabled MuscleView reportedly offers 3D analysis of muscle volume, muscle asymmetry and intramuscular fat.
The Food and Drug Administration (FDA) has granted 510(k) clearance for MuscleView, which provides three-dimensional (3D) visualization and analysis of muscle health based on artificial intelligence (AI) assessment of rapid magnetic resonance imaging (MRI) scans.
The MuscleView software enables enhanced assessment of muscle volume and asymmetry as well as intramuscular fat percentage and bone volume, according to Springbok Analytics, the manufacturer of the MuscleView software.
The newly FDA-cleared MuscleView software provides 3D visualization and analysis of muscle asymmetry and volume, intramuscular fat percentage and bone volume through AI-powered interpretation of rapid MRI scans. (Image courtesy of Springbok Analytics.)
The company says the capability of the MuscleView software, developed over 13 years of research, enables clinicians to have simplified 3D imaging of musculature and analysis of rapid MRI data, creating a “new standard” in muscle health assessment.
"We envision a future where a Springbok scan becomes a routine part of annual health check-ups and an integral part of preventive health — with scans even more frequent depending on performance goals, injuries and recovery, or other health considerations," noted Scott Magargee, the CEO and co-founder of Springbok Analytics. "Our goal is to empower individuals to better understand, monitor, and measure their muscle health across all stages of life."
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
